Tennessee Alzheimer's Project
TAP
2 other identifiers
observational
1,000
1 country
1
Brief Summary
The primary objective of the Vanderbilt Alzheimer's Disease Research Center (VADRC) is to provide local and national researchers with access to a well-characterized and diverse clinical cohort, including participant referrals, biosamples, clinical data, and neuroimaging data. The VADRC Clinical Core will create an infrastructure to support research efforts of both local and national investigator studies to develop early detection, prevention, and treatment strategies for Alzheimer's disease. The Clinical Core intends to enroll up to 1000 participants, including individuals who are cognitively unimpaired, have mild cognitive impairment, or have Alzheimer's disease. This cohort of about 1000 participants will be called the Tennessee Alzheimer's Project. Participants will be seen annually for comprehensive clinical characterization and then referred to other studies to enhance Alzheimer's disease research activities.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Oct 2021
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
October 27, 2021
CompletedFirst Submitted
Initial submission to the registry
January 27, 2022
CompletedFirst Posted
Study publicly available on registry
May 12, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 31, 2030
ExpectedStudy Completion
Last participant's last visit for all outcomes
March 31, 2030
February 5, 2026
July 1, 2025
8.4 years
January 27, 2022
February 2, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (13)
Cognitive status
Change in cognitive status assessed by the Uniform Dataset according to the National Institute on Aging and Alzheimer's Association Workgroup guidelines determined by a consensus team.
baseline to year 3
APOE Genotype
APOE e4 allele status
baseline to year 3
White matter hyperintensities Volume
White matter lesion volume measured by FLAIR imaging modality
baseline to year three
Grey Matter Volume
Grey matter volume measured by T1 imaging modality
baseline to year three
Cerebral Blood Flow
Resting cerebral blood flow to brain regions measured by T3 perfusion
baseline to year three
Lacunar infarcts
Number of lacunar infarcts measured by MRI
baseline to year three
Microbleeds
Number of microbleeds measured by MRI
baseline to year three
Left ventricular ejection fraction
Left ventricular ejection fraction measured by echocardiogram
baseline to year three
Cardiac output
Amount of blood the heart pumps from each ventricle per minute (litres per minute (L/min)), measured by echocardiogram
baseline to year three
Stroke volume
Stroke volume measured by echocardiogram
baseline to year three
Heart rate
Heart rate measured by echocardiogram
baseline to year three
Biological markers for Alzheimer's disease
Tau, amyloid, and neurodegenerative levels in cerebrospinal fluid samples
baseline to year three
Blood based biological marker for Alzheimer's disease
Tau, amyloid, and neurodegenerative levels in blood samples
baseline to year three
Study Arms (3)
Cognitively unimpaired
A consensus team determined cognitive status according to the National Institute on Aging and Alzheimer's Association Workgroup guidelines.
Mild cognitive impairment
A consensus team determined cognitive status according to the National Institute on Aging and Alzheimer's Association Workgroup guidelines.
Alzheimer's disease
A consensus team determined cognitive status according to the National Institute on Aging and Alzheimer's Association Workgroup guidelines.
Interventions
none, observational study
Eligibility Criteria
Community-dwelling older adults.
You may qualify if:
- Age 60 or older
- Meet standard criteria for (a) cognitively unimpaired, (b) mild cognitive impairment, or (c) Alzheimer's disease
- English speaking
- Individuals who lack decisional capacity to provide informed consent at baseline will not be enrolled in the study
You may not qualify if:
- No available reliable study partner (reliable is defined as someone who interacts significantly with the participant and is available to participate in study visits in person or by phone)
- History of major psychiatric illness (e.g., schizophrenia, bipolar), neurological illness (e.g., epilepsy, multiple sclerosis, Parkinson's disease), or head injury with significant loss of consciousness.
- Unable to undergo MRI (e.g., claustrophobia, ferrous metal in body)
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Vanderbilt University Medical Center
Nashville, Tennessee, 37232, United States
Biospecimen
Cerebral spinal fluid, plasma, serum, PAXGene, blood clot.
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Angela Jefferson, PhD
Professor of Neurology
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Professor of Neurology
Study Record Dates
First Submitted
January 27, 2022
First Posted
May 12, 2022
Study Start
October 27, 2021
Primary Completion (Estimated)
March 31, 2030
Study Completion (Estimated)
March 31, 2030
Last Updated
February 5, 2026
Record last verified: 2025-07
Data Sharing
- IPD Sharing
- Will not share